

| Application Number | Product | Status Reason | Decision Date | State (Consulting Location) (SAS Consulting Location) | Prescriber specialty (Prescriber) (SAS Prescriber) | Form Type | Strength / Dimensions |
|--------------------|--------------------------------------|---------------|---------------|---|--|-----------|---|
| MB20/0254029 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 15/05/2020 | NSW | Psychiatry | SAS-B | 120mg (up to 200mg) on three occasions |
| MB20/0275110 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 6/07/2020 | NSW | Specialist psychiatrist | SAS-B | 125mg-187.5mg as 3 doses as per protocol |
| MB20/0293914 | Psilocybin | Approved | 18/08/2020 | NSW | Specialist general practitioner | SAS-B | 1 capsule 3 sessions as per protocol |
| MB20/0298368 | Psilocybin | Approved | 25/08/2020 | NSW | Specialist psychiatrist | SAS-B | 25mg (unless patient weighs over 90kg) for one session |
| MB20/0298421 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 28/08/2020 | NSW | Specialist psychiatrist | SAS-B | 125mg-187.5mg on three occasions |
| MB20/0304379 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 9/09/2020 | NSW | Specialist psychiatrist | SAS-B | 125mg - 187.5mg on three occasions |
| MB20/0321733 | Psilocybin | Approved | 13/10/2020 | NSW | Specialist psychiatrist | SAS-B | As per protocol |
| MB20/0334265 | Psilocybin | Approved | 10/11/2020 | NSW | Specialist psychiatrist | SAS-B | As per protocol. |
| MB20/0343954 | Psilocybin | Approved | 26/11/2020 | NSW | Specialist psychiatrist | SAS-B | 25mg as a single dose, orally |
| MB20/0345728 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 3/12/2020 | NSW | Specialist psychiatrist | SAS-B | 80-120mg on three occasions as per protocol |
| MB20/0360383 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 23/12/2020 | NSW | Specialist psychiatrist | SAS-B | 125mg - 187.5mg on three occasions |
| MB21/0385184 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 12/02/2021 | NSW | Specialist psychiatrist | SAS-B | 125mg-187.5mg on three occasions |
| MB21/0386388 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 19/02/2021 | VIC | Psychiatry | SAS-B | 125mg - 187.5mg on three occasions |
| MB21/0390448 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 26/02/2021 | NSW | Specialist psychiatrist | SAS-B | Capsules 125mg + 62.5 PO 125mg - 187.5mg on 3 occasions |
| MB21/0395746 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 15/03/2021 | NSW | Specialist general practitioner | SAS-B | 125mg-187.5mg on three occasions. |
| MB21/0396279 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 11/03/2021 | NSW | Specialist psychiatrist | SAS-B | 125mg-187.5mg to be taken orally on three occasions |
| MB21-0476790 | 3,4-methylenedioxyamphetamine (MDMA) | Approved | 10/06/2021 | VIC | Specialist psychiatrist | SAS-B | 125mg -187.5mg on three occasions |

| Authorised Prescriber Number | Product Profile | Product Presentation | Decision date | State (Consulting Location) (SAS Consulting Location) | Prescriber specialty (Prescriber) (SAS Prescriber) |
|------------------------------|--|----------------------|---------------|---|--|
| MAP23-0053822 | 3,4-methylenedioxymethamphetamine (MDMA) | Capsule | 2/11/2023 | 47E0 | Specialist psychiatrist |
| MAP23-0051448 | Psilocybin | Tablet | 25/07/2023 | 47E0 | Psychiatry |
| MAP23-0053821 | Psilocybin | Capsule | 2/11/2023 | 47E0 | Specialist psychiatrist |